Clinical Trial: Intracerebroventricular Tralesinidase Alfa in Children With Mucopolysaccharidosis Type IIIB

U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07579910) titled 'Intracerebroventricular Tralesinidase Alfa in Children With Mucopolysaccharidosis Type IIIB' on April 28.

Brief Summary: The primary objectives of this study are to evaluate the effects of Tralesinidase Alfa (TA) on cognition

Study Start Date: Dec., 2026

Study Type: INTERVENTIONAL

Condition: MPS IIIB

Intervention: DRUG: Tralesinidase alfa (TA)

TA study drug is a sterile solution for ICV infusion.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Spruce Biosciences

Disclaimer: Curated by HT Syndication....